综述文章：免疫检查点抑制剂和肝脏，从治疗效果到副作用

StephenW

Aliment Pharmacol Ther. 2019 Aug 4. doi: 10.1111/apt.15449. [Epub ahead of print]
Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects.
Lombardi A1,2, Mondelli MU1,2.
Author information

1
    Division of Infectious Diseases II and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
2
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Abstract
BACKGROUND:

Immune checkpoint inhibitors have revolutionised the oncological landscape in the last few years. Possible applications include the treatment of hepatocellular carcinoma and cholangiocarcinoma. Unfortunately, new immune-related adverse effects have been associated with the use of these agents and the liver is one of the organs most frequently involved.
AIMS:

To provide a general overview of the potential impact of immune checkpoint inhibitors on the liver METHODS: We reviewed the literature and abstracts/presentations on immune checkpoint inhibitors at most relevant hepatology meetings over the last 5 years.
RESULTS:

The role of immune checkpoint inhibitors has been investigated both for the treatment of viral hepatitis and primary liver cancer. Hepatocellular carcinoma and chronic hepatitis B show the greatest potential for treatment with these drugs in the near future. However, immune-related adverse events involving the liver are a growing concern related to their widespread use.
CONCLUSIONS:

Immune checkpoint inhibitors represent an exciting new class of drugs with currently limited application in malignant and non-malignant liver disease. Caution must be exercised on the emergence of potentially severe immune adverse reactions.

© 2019 John Wiley & Sons Ltd.

PMID:
    31378985
DOI:
    10.1111/apt.15449

StephenW

Aliment Pharmacol Ther。 2019年8月4日doi：10.1111 / apt.15449。 [印刷前的电子版]
综述文章：免疫检查点抑制剂和肝脏，从治疗效果到副作用。
Lombardi A1,2，Mondelli MU1,2。
作者信息

1
传染病科II和免疫学，医学科学和传染病科，Fondazione IRCCS Policlinico San Matteo，帕维亚，意大利。
2
意大利帕维亚帕维亚大学内科和治疗学系。

抽象
背景：

免疫检查点抑制剂在过去几年中彻底改变了肿瘤学领域。可能的应用包括治疗肝细胞癌和胆管癌。不幸的是，新的免疫相关副作用与这些药物的使用有关，肝脏是最常见的器官之一。
目的：

概述免疫检查点抑制剂对肝脏的潜在影响方法：我们在过去5年的大多数相关肝病学会议上回顾了免疫检查点抑制剂的文献和摘要/介绍。
结果：

已经研究了免疫检查点抑制剂在治疗病毒性肝炎和原发性肝癌中的作用。在不久的将来，肝细胞癌和慢性乙型肝炎最有可能用这些药物治疗。肝脏是其广泛使用的相关问题。
结论：

免疫检查点抑制剂代表了一类令人兴奋的新型药物，目前在恶性和非恶性肝病中的应用有限。必须注意潜在的严重免疫不良反应的出现。

©2019 John Wiley＆Sons Ltd.

结论：
31378985
DOI：
10.1111 / apt.15449

StephenW

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.15449